Month: September 2026

BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient has completed their last visit in the Company’s Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).

The randomized, double-blind, placebo-controlled Phase 2a trial, known as INFORM-MS (NCT06292923), enrolled a total of 48 patients across three cohorts at multiple leading U.S. clinical sites. The study is evaluating the safety, tolerability, and efficacy of two doses of intranasal foralumab versus placebo over a 12-week treatment period, with the primary endpoint focused on change in microglial activation as measured by positron emission tomography (PET) imaging, along with secondary clinical endpoints including the Expanded Disability Status Scale (EDSS) and the Modified Fatigue Impact Scale (MFIS). Tiziana expects to lock the database this week, and announce 12-week treatment topline data in October.

Following completion of the blinded phase, all participants, including those who initially received placebo, have the opportunity to receive intranasal foralumab in a six-month follow on open-label extension (OLE). The OLE is designed to generate longer term safety and efficacy data. Encouragingly, data from the Company’s Expanded Access Program in na-SPMS have shown that most patients treated with intranasal foralumab either stabilized or improved in clinical outcomes over an extended treatment duration.

“I congratulate the entire Tiziana team, our clinical investigators, study sites, and most importantly the patients and their families who made this milestone possible,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “Completing the last patient last visit in our Phase 2a INFORM-MS trial is a significant achievement. The dedication and hard work of everyone involved have brought us to this important point in the development of intranasal foralumab for patients living with na-SPMS, a condition with unmet medical need. We look forward to unblinding and presenting the topline data next month.”

About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923), as well as additional Phase 2 trials in AD and MSA.

Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of Tiziana’s management and include statements regarding the closing of the Offering. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the SEC from time to time. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

To the Nasdaq Copenhagen

21 September 2026

Debtor distribution data (CK92)

Pursuant to s 24 Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes debtor distribution data for callable mortgage bond series as at 18 September 2026 in the attached file.

Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/filarkiv/.

For further information about data format and contents, please refer to the Nasdaq website.

Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.

Yours sincerely
Nykredit Realkredit A/S

Attachments

• Debtor distribution data – Nykredit Realkredit A_S 21-09-2026
• debisams_21092026

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken:	18th September 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	35,703	282	281.5
Ordinary shares	Sales	515,471	282	281.5

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	21st September 2026
Contact name:	Priyali Bhattacharjee
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

VANCOUVER, British Columbia, Sept. 21, 2026 (GLOBE NEWSWIRE) — Methanex Corporation (the “Company” or “Methanex”) (TSX: MX) (Nasdaq: MEOH) announced today that it has issued a notice of partial redemption for US$300 million of its outstanding 5.125% senior notes due October 15, 2027. The redemption date is October 19, 2026.

Rich Sumner, President and CEO, Methanex Corporation, stated, “Today’s announcement is underpinned by the company’s strong cash position and cash flow generation capability, resulting from continued tight global methanol market conditions combined with production from our significantly strengthened asset base, and is aligned with our commitment to progress towards our stated balance sheet leverage target.”

ABOUT METHANEX

Methanex is a Vancouver-based, publicly traded company and is the world’s largest supplier of methanol globally. Methanex shares are listed for trading on the Toronto Stock Exchange in Canada under the trading symbol “MX” and on the Nasdaq Stock Market in the United States under the trading symbol “MEOH”. Methanex can be visited online at www.methanex.com.

FORWARD-LOOKING INFORMATION WARNING

This news release contains certain forward-looking statements, or forward-looking information, with respect to us and our industry. These statements relate to future events or our future performance. All statements other than statements of historical fact are forward-looking statements. Statements that include the word “will” or other comparable terminology and similar statements of a future or forward-looking nature identify forward-looking statements.

Forward-looking statements, by their nature, involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Factors that may cause actual results to vary include, but are not limited to, risks relating to conditions in the financial markets and other risk factors as detailed from time to time in Methanex’s reports filed with Canadian securities administrators and the U.S. Securities and Exchange Commission. Certain of these risks are described in more detail in our 2025 Annual Management’s Discussion and Analysis and Second Quarter 2026 Management’s Discussion and Analysis and in our public filings with Canadian securities administrators and the U.S. Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on forward-looking statements. They are not a substitute for the exercise of one’s own due diligence and judgment. The outcomes implied by forward-looking statements may not occur and we do not undertake to update forward-looking statements except as required by applicable securities laws.

Inquiries:
Robert B. Winslow, CFA
Vice President, Investor Relations
Methanex Corporation
604-661-2600 or Toll Free: 1-800-661-8851
www.methanex.com

• Strategic collaboration accelerates Einride’s push into highway and suburban autonomous trucking.
• Einride will adapt the NVIDIA DRIVE Hyperion platform for heavy-duty trucking, working directly with NVIDIA to extend the platform’s compute, sensor, software and safety architecture to the demands of heavy-duty freight.
• Building the next generation of the Einride Driver on NVIDIA Hyperion platform, will enable Einride to scale autonomous deployment across a freight network that’s already serving customers today.

STOCKHOLM, Sept. 21, 2026 (GLOBE NEWSWIRE) — Einride AB (Nasdaq: ENRD) (“Einride” or the “Company”), a technology company driving the transition to cost-efficient autonomous and electric freight for some of the world’s largest shippers, today announced a collaboration with NVIDIA to further accelerate the transition of the Company’s extensive freight network to autonomous operations.

Einride develops and integrates the technologies required to create cost-efficient autonomous and electric freight networks for its global shipping customers. Einride currently operates hundreds of electric trucks for major shippers across the U.S., Europe, and the Middle East, including autonomous trucks already operating in contracted customer deployments. This footprint is expected to scale to 1,500-2,000 vehicles by 2028, based on customer demand captured on its platform so far, and approximately 80% of that demand is suitable for automation in the medium term as the company continues to advance its autonomous technology.

Einride designs, builds, and operates the autonomous-driving system end-to-end, including safety validation, regulatory approval, and contracted customer deployments, while NVIDIA provides the underlying compute platform and AI development tools that support the system.

“We have the customers, the operational experience and the technology. Building the next generation of the Einride Driver on the NVIDIA Hyperion platform, will enable us to scale autonomous deployment across a freight network that’s already serving customers today,“ said Henrik Green, Chief Technology Officer at Einride.

“Autonomous trucking represents one of the clearest opportunities to improve the safety and efficiency of global freight,” said Rishi Dhall, vice president of automotive at NVIDIA. “By building on NVIDIA Hyperion with the NVIDIA Halos safety system and using NVIDIA Cosmos and Blackwell infrastructure, Einride can accelerate the development and validation of its autonomous-driving technology and scale deployments across its growing freight network.”

Built on the NVIDIA Hyperion platform, a production-ready compute and sensor reference architecture for Level 4 autonomy, and integrated with the NVIDIA Halos safety system, the collaboration creates a scalable foundation that accelerates safe, production-ready autonomous freight operations for Einride.

Einride intends to deploy NVIDIA Blackwell architecture at scale with an NVIDIA Exemplar Cloud partner, a cloud provider whose infrastructure NVIDIA has validated for large-scale AI training performance, to train, test and refine its autonomous driving models. This is a compute and development infrastructure that supports Einride’s own autonomous-driving stack.

Einride will adapt the NVIDIA Hyperion platform for heavy-duty trucking, working directly with NVIDIA to extend the platform’s compute, sensor, software and safety architecture to the demands of heavy-duty freight. As part of its AI development workflow, Einride is using NVIDIA Cosmos to help improve the safety and reliability of its autonomous vehicles. NVIDIA Cosmos enables Einride to search and curate camera data to identify complex edge cases, as well as augment real-world data with photorealistic synthetic scenarios that increase the diversity of data used for AI training and validation.

About Einride

Founded in Stockholm in 2016, Einride (Nasdaq: ENRD) is a technology leader driving the transition to sustainable, cost-efficient autonomous and electric freight operations. The company’s platform integrates AI-powered freight intelligence, proprietary autonomous technology, and one of the world’s largest electric heavy-duty fleets. Einride serves a global customer base across North America, Europe, and the Middle East through a dual business model encompassing Freight-Capacity-as-a-Service (FCaaS) and a software platform.

Investor & Media Contacts
Christina Zander
Head of Communications, Einride
press@einride.tech, einride@icrinc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/967e7af8-18f2-499b-81de-182b68ded31f

Templin to advance growth, talent, operations, innovation and customer experience across the Company’s employee benefits business

DAYTONA BEACH, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (“the Company”) today announced the appointment of Erik Templin as executive managing director, employee benefits, North America, within the Company’s Retail segment. In this role, Templin will lead the Company’s employee benefits business across North America, with responsibility for shaping and executing strategy across growth, talent, operations, innovation and the customer experience.

Reporting to Steve Hearn, president, Brown & Brown Retail, Templin will partner with senior leadership to advance the Company’s employee benefits strategy, strengthen sales execution, deepen customer relationships, support operational alignment and continue building a scalable, high-performing organization across markets.

With more than 25 years of experience across employee benefits, healthcare information services, pharmaceutical and third-party administrator environments, Templin brings a broad perspective on the evolving needs of employers and their workforce strategies.

“Erik is a strong operator and a proven strategic leader who understands how to build teams, develop talent and deliver results,” said Hearn. “He knows our business, he knows our customers and he knows how to support producers and teammates in a way that drives meaningful, sustainable growth. I am excited to see him continue to lead and build on the strong momentum across our employee benefits business.”

Templin joined Brown & Brown in 2018 through acquisition and has held a series of leadership roles of increasing scope and responsibility, including regional vice president, regional managing director and senior managing director. Throughout his tenure, he has helped expand the Company’s employee benefits platform, cultivate future leaders and drive sustainable organic growth across multiple markets.

“I am honored to help lead the next phase of growth for Brown & Brown’s employee benefits business,” said Templin. “Our success starts with our people. What excites me most is the quality of our teammates, the strength of our customer relationships and the opportunity to bring the best of our local specialization together across the organization. I look forward to working alongside our leaders and teammates to accelerate growth, invest in talent, strengthen operational excellence and create lasting value for our customers.”

About Brown & Brown, Inc.

Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of approximately 23,000 professionals, we are dedicated to delivering scalable, innovative strategies for our customers at every step of their growth journey. Learn more at BBrown.com.

This press release may contain certain forward-looking statements relating to future results. These statements are not historical facts but instead represent only Brown & Brown’s current belief regarding future events, many of which, by their nature, are inherently uncertain and outside of Brown & Brown’s control. It is possible that Brown & Brown’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further information concerning Brown & Brown and its business, including factors that potentially could materially affect Brown & Brown’s financial results and condition, as well as its other achievements, is contained in Brown & Brown’s filings with the Securities and Exchange Commission. All forward-looking statements made herein are made only as of the date of this release, and Brown & Brown does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which Brown & Brown hereafter becomes aware.

For more information:

Jenny Goco
Vice President of Public Relations & Communications
(386) 333-6066
jenny.goco@bbrown.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/afa65b58-bbdd-466c-91ed-d29fb43d186c

New York, Sept. 21, 2026 (GLOBE NEWSWIRE) — Namib Minerals (“Namib Minerals” or “the Company”) (Nasdaq: NAMM), an established African gold producer with a portfolio of mining assets in Zimbabwe, today announced the completion of the dewatering programme at Redwing Mine, the first of the five steps in the restart pathway the Company set out on July 20, 2026.

On July 20, 2026, Namib Minerals published a defined five-step pathway and targeted milestone schedule for the restart of Redwing Mine, with dewatering as Step 1 and completion targeted for Q4 2026. That step is now complete, ahead of the targeted schedule.

Completion of dewatering restores safe access to the underground workings, enabling underground mapping, sampling and the geotechnical and hydrological work programmes that feed the technical programme of the Definitive Feasibility Study (“DFS”). The DFS technical programme remains fully funded through to completion and on track to conclude in early Q1 2027, unchanged from the schedule published in July.

Tulani Sikwila, Chief Executive Officer and Chairman of Namib Minerals, commented: “Dewatering was the gateway to everything that follows at Redwing, and we have delivered it ahead of the schedule we published. We set out a five-step pathway in July precisely so that our shareholders could measure us against it. Step one is done, step two is funded and underway, and we intend to keep reporting against that same map.”

Redwing Restart Pathway

Step	Scope	Target	Status
1 – Dewatering	Staged pumping to safely access underground workings	Q4 2026	Completed
2 – DFS technical programme	Engineering, metallurgical, geotechnical, hydrological, environmental and financial workstreams; fully funded	Early Q1 2027	Underway
3 – Resource definition and bankability	8,750-metre surface exploration drilling and associated work	Q4 2027	Next funding stage
4 – Construction	Staged restart capital mobilisation and construction on a positive decision	Upon DFS completion	—
5 – Restart	Commissioning and phased return to production	Following construction	—

About Namib Minerals

Namib Minerals (NASDAQ: NAMM) is a gold producer, developer and explorer with operations focused in Zimbabwe. Currently Namib Minerals operates the How Mine, an underground gold mine in Zimbabwe, and aims to restart two assets in Zimbabwe. For additional information, please visit namibminerals.com.

Forward-Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that refer to restarts of mines, future financing or other future events or circumstances, including any underlying assumptions, are also forward-looking statements. Forward-looking statements include, without limitation, statements regarding the Company’s governance and leadership structure, its financing programme and the planned restart of the Redwing Mine. Forward-looking statements are based on current expectations, are inherently subject to uncertainties and changes in circumstance, and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These statements involve a number of risks and uncertainties described in the filings we make with the Securities and Exchange Commission, and you should carefully consider those factors. We caution you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made.

Contact:

Investor Relations:
Investor.relations@namibminerals.com 

Bimergen Energy invites individual and institutional investors, as well as advisors and analysts, to attend its presentation at the Emerging Growth Conference.

NEWPORT BEACH, CA, Sept. 21, 2026 (GLOBE NEWSWIRE) — Bimergen Energy (NYSE American: BESS), a U.S.-based renewable energy infrastructure developer, owner and operator (the “Company”), is pleased to announce that it will provide an update at the Emerging Growth Conference on September 23, 2026, from 3:55-4:05 p.m. Eastern Time.

The Emerging Growth Conference will take place on September 23, 2026. During Bimergen Energy’s presentation, Co-CEO Bob Brilon will provide shareholders and the broader investment community with an update on the Company’s progress and strategic initiatives. The presentation is scheduled for 3:55–4:05 p.m. Eastern Time.

To first view the Company’s previous presentation:
Click here for Bimergen’s previous presentation

Bimergen Energy will present on September 23, 2026, from 3:55-4:05 p.m. Eastern Time for 10 minutes.

Please register here to ensure you are able to attend the conference and receive any updates that are released.

Register Here

If attendees are unable to join the event live, an archived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube channel at www.YouTube.com/EmergingGrowthConference. A link will be released after the event.

About the Emerging Growth Conference

The Emerging Growth Conference is an effective way for public companies to present and communicate new products, services and other major announcements to the investment community from the convenience of their offices in a time-efficient manner.

The conference focuses on companies in a wide range of growth sectors with strong management teams, innovative products and services, focused strategies, execution, and the potential for long-term growth. Its audience includes individual and institutional investors, as well as investment advisors and analysts.

All sessions are conducted through video webcasts and take place in the Eastern time zone.

About Bimergen Energy

Bimergen Energy (NYSE American: BESS) is a U.S.-based renewable energy infrastructure developer, owner and operator focused on utility-scale battery energy storage systems. Bimergen Energy develops and operates infrastructure designed to enhance grid stability and support the integration of renewable generation across key U.S. markets. The Company generates operating revenue by buying energy at lower off-peak prices and selling it back to the same grid at higher peak prices. For more information, visit www.Bimergen.com.

Contact
RedChip Companies, Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
Bess@redchip.com